SCHEMBL7795061

SCHEMBL7795061

CSc1ncc2cc(C)c(=O)n(C)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 7/20 0.38
SRC P12931 5/20 0.38
KDM4E B2RXH2 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
FGFR1 P11362 5/20 0.36
EGFR P00533 4/20 0.36
FGFR2 P21802 3/20 0.36
FGFR4 P22455 3/20 0.36
FGFR3 P22607 3/20 0.36
BRPF1 P55201 1/20 0.36
ABL1 P00519 3/20 0.36
PDGFRB P09619 2/20 0.36
PDGFRA P16234 2/20 0.36
MAPK14 Q16539 2/20 0.36
BMPR1B O00238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31425826 1.00 WEE1 (0.38) WEE1SRCKDM4EPSEN1PSEN2
SCHEMBL31532056 0.84 PSEN1 (0.35) WEE1SRCKDM4EPSEN1PSEN2
SCHEMBL27382632 0.83 PSEN1 (0.36) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL31635961 0.83 FGFR1 (0.44) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL26113871 0.83 MAPK14 (0.39) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL30597112 0.83 MAPK14 (0.39) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL5061806 0.83 WEE1 (0.39) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL29357943 0.83 WEE1 (0.39) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL20563501 0.83 FGFR1 (0.44) WEE1SRCPSEN1PSEN2APH1B
SCHEMBL13553947 0.82 FGFR1 (0.37) WEE1SRCPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404695-B2 Pyrimidinyl pyridone inhibitors of JNK ROCHE PALO ALTO LLC (US) 2013-03-26 US disclosed
US-8404695-B2 Pyrimidinyl pyridone inhibitors of JNK ROCHE PALO ALTO LLC (US) 2013-03-26 US disclosed
WO-2010046273-A2 PYRIMIDINYL PYRIDONE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2010-04-29 WO disclosed
US-20100099691-A1 PYRIMIDINYL PYRIDONE INHIBITORS OF JNK ROCHE PALO ALTO LLC 2010-04-22 US disclosed
US-20100099691-A1 PYRIMIDINYL PYRIDONE INHIBITORS OF JNK ROCHE PALO ALTO LLC 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099691-A1 PYRIMIDINYL PYRIDONE INHIBITORS OF JNK MAP3K20, MAP3K6, MAP3K1 WEE1 1242/4885SRC 924/4885KDM4E 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.